# PeriVision

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/perivision

- Industry: Medical Devices & Equipment
- Headquarters: Epalinges, Switzerland
- Website: www.perivision.com
- Total disclosed funding: $3M
- Latest round: Seed (Sep 12, 2025)
- Investors on record: 6

## About

Based in Switzerland, PeriVision SA provides advanced solutions for eye care, focusing on innovative diagnostics and monitoring tools for glaucoma through its VisionOne™ platform.PeriVision SA, founded in 2022 and headquartered in Epalinges, Switzerland, specializes in creating technology-driven solutions for eye care. In September 2025, PeriVision raised CHF 2.4 million in seed funding led by Arya Investment Platform, with participation from DART Ventures, Zuhlke Group Ventures, MEDKAP Investor Association, SICTIC, Venture Kick, Is Bank’s AI Startup Factory, CADFEM Europe, OOMNIUM AG, INATEC, Juchum Foundation, and others unspecified investors. The company was co-founded by Patrick Kessel (CEO), Dr. Serife Kucur Ergunay, and Prof. Dr. Raphael Sznitman. PeriVision offers a platform called VisionOne™, which addresses challenges in eye care, particularly in diagnosing and monitoring glaucoma. Its primary product is a virtual reality (VR) visual field testing tool that allows eye care professionals to conduct tests efficiently using portable VR headsets. This system leverages artificial intelligence to optimize testing processes, aiding clinical decisions. PeriVision's tools are utilized by eye doctors and healthcare professionals across the United States and Switzerland, focusing on North American and European markets.PeriVision's revenue model is built on subscription services and partnerships with healthcare institutions, facilitating direct business-to-business transactions. Clients subscribe to access the VisionOne™ platform and VR testing tools, which include ongoing support and AI-driven updates. This model caters to both small practices and larger healthcare networks, aiming to meet the increasing demand for advanced eye care solutions while establishing partnerships with leading clinics for collaborative research and product validation.In September 2025, PeriVision secured CHF 2.4 million in Seed funding to accelerate the development of its VR platform targeting retinal diseases. This funding will support technological advancements and integration solutions for eye clinics, optometry practices, and biopharma partners. The company aims to expand its market reach by launching new products designed for retinal care and targeting additional geographical regions, although specific regions for expansion have not been disclosed.

## Funding rounds

- Seed, Sep 12, 2025, $3M — Zuhlke Ventures, Swiss Startup INVEST, Venture Kick, DART Ventures, Arya Women Investment Platform, Cadfem Group

## Investors

- Zuhlke Ventures (https://capitalatlas.ai/funds/zuhlke-ventures) — Seed
- Swiss Startup INVEST (https://capitalatlas.ai/funds/swiss-startup-invest) — Seed
- Venture Kick (https://capitalatlas.ai/funds/venture-kick) — Seed
- DART Ventures (https://capitalatlas.ai/funds/dart-ventures) — Seed
- Arya Women Investment Platform (https://capitalatlas.ai/funds/arya-women-investment-platform) — Seed
- Cadfem Group — Seed